Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(319)
•••
Comment by Claridgeon Jun 19, 2019 5:45pm
53 Views
Post# 29841784

RE:Lung cancer: BPMC shrank tumors in 60% of a specific cohort

RE:Lung cancer: BPMC shrank tumors in 60% of a specific cohort
More on their NSCLC niche market:
 
 
Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC).

_________________

Claridge - (6/19/2019 5:31:21 PM) 

Lung cancer: BPMC shrank tumors in 60% of a specific cohort

BPMC now has a market cap of 4.7B$US, its highest since May 2015.

Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array 11.4B$ Deal


As expected, there has been an accelerated pace of merger and acquisitions (M&A) activity in pharma space this year, especially in cancer. We have already seen some major deals this year. In January, Bristol-Myers offered to buy Celgene for$74 billion, followed by Lilly’s acquisition of Loxo Oncology for $8 billion in February.


Blueprint Medicines Corporation (BPMC)


With a market cap of $4.61 billion, Blueprint Medicines Corporation (BPMC) is a precision therapy company focused on genomically defined cancers and cancer immunotherapy. 

The Cambridge, Massachusetts-based company said earlier this month that its inhibitor BLU-667 shrank tumors in 60% of a difficult-to-treat group of lung cancer patients and that it's preparing for a 2020 filing in patients with RET-altered non-small cell lung cancer who had already tried chemotherapy.


Pipeline | Blueprint Medicines

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities